FDA Clears IMDx's MDx for Vancomycin-resistant Enterococci | GenomeWeb

NEW YORK (GenomeWeb News) – IntelligentMDx today announced it has received clearance from the US Food and Drug Administration for its molecular diagnostic test for vancomycin-resistant enterococci.

IMDx's assay detects the presence of vanA and vanB genes that have been associated with vancomycin-resistant enterococci, which are responsible for healthcare-related infections that include surgical wounds, urinary tract, and bloodstream infections.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.